NanoBio

Ann Arbor Firm’s Technology Makes Vaccines More Effective

NanoBio Corp. Tuesday said that it is presenting new data demonstrating positive pre-clinical results for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.

WWJ Newsradio 950–2013/04/23

HR Notices From October 8

The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions nad groiups

WWJ Newsradio 950–2012/10/09

NanoBio To Report Data On New RSV Vaccine At Symposium

NanoBio Corp. announced Monday it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus Symposium taking place Sept. 27-30 in Santa Fe, N.M.

WWJ Newsradio 950–2012/09/24

NanoBio In RSV Vaccine Research Effort With Merck

Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).

WWJ Newsradio 950–2011/12/08

NanoBio’s Intranasal Vaccine Induces Robust Immunity in Animals

NanoBio Corp. announced Wednesday that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus vaccine have shown strong immunity effects, paving the way for more studies of the nanoparticle-based technology.

WWJ Newsradio 950–2011/08/24

NanoBio Secures Novel Antigen Source For Intranasal RSV Vaccine

Ann Arbor-based NanoBio Corp. last week announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

WWJ Newsradio 950–2011/08/08

NanoBio Publishes Study Results For Intranasal Nanoemulsion Vaccine

Ann Arbor-based NanoBio Corp. says newly published experimental data shows that its nanoemulsion-based flu vaccine has elicited robust immunity to the flu in animal tests on ferrets.

WWJ Newsradio 950–2011/07/20

NanoBio: First Patients Vaccinated In Phase 1B Nasal Flu Vaccine Study

Building upon a series of successful preclinical and clinical studies, Ann Arbor-based NanoBio Corp. Tuesday announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant.

WWJ Newsradio 950–2011/06/21